Pay in 4 interest-free payments of $5.25 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Inhibitory Growth of Oral Squamous Cell Carcinoma Cancer via Bacterial Prodigiosin
Response to GLP-1RA was initially assessed by comparing the response to treatment of 1,119 participants with T2D treated with GLP-1RA in a meta-analysis of the three similar cohorts Innovative Medicines Initiative DIabetes REsearCH on patient straTification (IMI-DIRECT) [29], Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS) [30] and Predicting Response to Incretin Based Agents (PRIBA) [31] and replication was sought in the methodologically different GSK-HARMONY Trial [32] and the EXSCEL Trial [33]
Thus, there is little data from which to draw conclusions about its safety, especially regarding long-term use in humans [2]
Delzenne NM, Bindels LB, Neyrinck AM, Walter J
Clinical studies suggest that GLP 1 & GIP therapy may be even more effective than GLP 1 alone, with patients often experiencing greater weight loss in a shorter period
